Biochemical modulation of 5-fluorouracil by folinic acid or alpha-interferon with and without other cytostatic drugs in gastric, esophageal, and pancreatic cancer.

Paper

Biochemical modulation of 5-fluorouracil by folinic acid or alpha-interferon with and without other cytostatic drugs in gastric, esophageal, and pancreatic cancer.

Published Apr 1, 1992 · H. Wilke, M. Stahl, H. Schmoll

Seminars in oncology

Q1 SJR score

10

Citations

0

Influential Citations

Semantic Scholar

Abstract

5-Fluorouracil (5-FU) is one of the important antineoplastic agents for the treatment of gastrointestinal cancers. The biochemical modulation of 5-FU by various drugs has brought about the two combinations of 5-FU/folinic acid (FA) and 5-FU/alpha-interferon (IFN), which have shown clinical activity in phase II and III trials, especially in colorectal cancer. The experience with both combinations in upper gastrointestinal cancers, however, is limited. In esophageal cancer, two phase II studies with 5-FU/IFN reported seven (27%) objective remissions in 26 patients, indicating superiority of 5-FU/IFN over 5-FU monotherapy. Trials with 5-FU/FA alone are lacking in esophageal cancer. The modulation of 5-FU by IFN or FA failed to show clinically significant activity in pancreatic cancer. However, in gastric cancer, 5-FU/FA and 5-FU/IFN seem to induce higher complete and overall remission rates in advanced gastric cancer compared with 5-FU alone. With the daily times five schedule of 5-FU/FA, 27% objective remissions were achieved; in combination with other cytotoxic drugs, such as etoposide, anthracyclines, cisplatin, mitomycin, or methotrexate, objective response rates up to 50% and more were reported.

Non-RCT

Study Snapshot

5-Fluorouracil combined with folinic acid or alpha-interferon shows potential in esophageal cancer, but not in pancreatic cancer, and may induce higher remission rates in advanced gastric cancer compared to 5-FU alone.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Biochemical modulation of 5-fluorouracil by folinic acid or alpha-interferon with and without other cytostatic drugs in gastric, esophageal, and pancreatic cancer.

Sign up to use Study Snapshot

References

Citations

Comparative effects of surfactants on the behavior of an anticancer drug potentiometric sensor

Surfactants, such as benzalkonium chloride, can enhance the performance of a 5-fluorouracil potentiometric sensor, providing a wide concentration range, low detection limit, and short response time.

Review of second-line chemotherapy for advanced gastric adenocarcinoma.

Second-line chemotherapy in advanced gastric adenocarcinoma shows similar response rates to other cancers and may provide longer survival and symptomatic benefit.

A Pilot Trial of Combination Cisplatin, 5-Fluorouracil and Interferon-α in the Treatment of Advanced Esophageal Carcinoma

The combination of cisplatin, 5-fluorouracil, and interferon- shows a high response rate in advanced squamous cell esophageal carcinoma, but with considerable toxicity.

Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagus

The combination cisplatin, etoposide, 5-fluorouracil, and folinic acid is a safe and effective regimen for advanced squamous cell carcinoma of the esophagus, with mucositis being the most prevalent toxicity.

Adjuvante Chemo- und Radiotherapie beim Pankreaskarzinom

Adjuvant chemo- or radiotherapeutic treatment for pancreatic cancer patients cannot be demanded as a routine measure, and individual decisions for adjuvant treatment should be made at the discretion of the treating institution.